Skip to content
stoqly

Zevra Therapeutics, Inc.

ZVRA Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Revenue Total sales reported in the income statement.
$106M
350.9% vs prior year
Operating margin Operating income as a share of revenue.
−59.1%
309.4 pts
Net income Profit after all expenses, interest and tax.
$83.2M
Free cash flow Cash from operations minus capital spending.
−$2.4M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−236.3%
4.7 pts
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On $0.94 EPS (TTM)

What Zevra Therapeutics, Inc. does

No business description yet.

Legal name
ZEVRA THERAPEUTICS, INC.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Mar 9, 2026
Accession · CIK
0001434647-26-000011
0001434647

Revenue and margins

Zevra Therapeutics, Inc. had $106M of revenue in fiscal 2025, up 350.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$2.4M in fiscal 2025, −2.3% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Zevra Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 23.8%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Zevra Therapeutics, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $112M$82.4M$67.7M$69.5M$191M
Debt incl. finance leases ——$5.1M$59.5M$61.9M
Debt / equity ——0.1x1.5x0.4x
Interest coverage 34.2x−127.1x−33.0x−11.8x−7.9x
Current ratio 27.2x7.7x1.2x2.5x5.7x
Quick ratio 27.2x7.7x1.2x2.5x5.6x
Total assets $133M$115M$172M$178M$285M
Total liabilities $5.8M$40.2M$110M$138M$130M
Shareholders' equity $102M$75.1M$61.9M$39.7M$155M
Net debt (− = net cash) ——−$62.7M−$10.0M−$129M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓
Cash from operations is positive ✕ ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✕ ✕
Return on assets rose — ✕ ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✓
Cash from operations exceeds net income ✕ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✕
Debt fell relative to assets — — ✕ ✕ ✓ — — — ✕ ✓
Current ratio rose — ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✓ ✓
Share count didn't rise — ✕ ✕ ✓ ✕ ✕ — — — ✕
Gross margin rose — — — — — — ✓ ✕ — —
Revenue rose relative to assets — — — ✓ ✕ ✕ ✕ ✓ ✕ ✓
F-score — / 3— / 61 / 73 / 83 / 84 / 72 / 72 / 72 / 75 / 8
Accruals ratio 15.6%−15.0%−5.7%−4.2%−99.7%−26.4%−6.5%−8.7%−20.5%36.7%
Altman Z'' −2.58−10.76−38.88−89.20−78.9417.64−5.92−8.41−10.32−0.84

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue — — $0.0M $12.8M $13.3M $28.7M $10.2M $27.5M $23.6M $106M
Gross profit — — $0.0M $2.8M — $26.6M $9.9M $24.5M — —
Research and development $20.5M $20.6M $41.8M $19.4M $8.8M $10.2M $19.8M $39.8M $42.1M $12.7M
Operating income −$37.5M −$33.4M −$55.9M −$20.3M −$5.6M $7.7M −$42.6M −$49.6M −$87.0M −$62.9M
Interest expense $5.5M $5.8M $5.5M $4.9M $4.8M $0.2M $0.3M $1.5M $7.4M $8.0M
Pretax income −$16.5M −$43.4M −$56.6M −$24.5M −$12.8M −$8.5M −$26.8M −$46.0M −$90.1M $86.7M
Income tax −$0.0M −$0.0M −$0.1M −$0.0M −$0.0M $0.0M −$0.0M $0.0M $15.4M $3.4M
Net income −$16.5M −$43.4M −$56.5M −$24.5M −$12.8M −$8.6M −$26.8M −$46.0M −$106M $83.2M
Net income to common — — — — −$12.8M −$62.9M −$26.8M −$46.0M −$106M $77.6M
Diluted EPS −$1.13 −$2.96 −$3.15 −$13.23 −$3.21 −$2.11 — — −$2.28 $1.35
Diluted shares 0.01B 0.01B 0.02B 0.00B 0.00B 0.03B — — 0.05B 0.06B
Cash flow
Cash from operations −$29.8M −$33.1M −$54.2M −$23.7M −$1.9M $10.4M −$18.7M −$33.5M −$69.7M −$1.6M
Capital expenditure $0.6M $0.2M $0.0M $0.0M $0.0M $0.1M $0.1M $0.3M $0.0M $0.8M
Free cash flow −$30.4M −$33.3M −$54.2M −$23.8M −$2.0M $10.3M −$18.8M −$33.8M −$69.7M −$2.4M
Depreciation and amortization $0.2M $0.3M $0.3M $0.3M $0.3M $0.3M $0.9M $1.0M $6.4M $4.1M
Stock-based compensation $6.6M $4.6M $6.5M $4.4M $2.5M $2.4M $4.3M $6.0M $14.9M $12.6M
Acquisitions — — — — — $0.0M $14.1M $30.4M $0.0M —
Share buybacks — — — — $0.0M $2.8M $4.7M $3.4M $0.0M —
Dividends and buybacks — — — — $0.0M $2.8M $4.7M $3.4M $0.0M —
Balance sheet
Cash and short-term investments $67.8M $42.2M $21.7M $3.2M $4.2M $112M $82.4M $67.7M $69.5M $191M
Total debt — $92.7M $81.4M $77.3M $67.7M — — $5.1M $59.5M $61.9M
Finance lease liabilities — — — $0.4M $0.2M $0.0M $0.0M $0.0M — —
Current assets $74.4M $45.9M $23.7M $7.0M $8.4M $115M $92.8M $86.9M $86.0M $223M
Current liabilities $6.6M $11.5M $12.0M $5.4M $7.5M $4.2M $12.0M $73.7M $34.1M $39.3M
Inventory — — — — — — $0.7M $0.0M $2.0M $1.7M
Property and equipment, net $2.0M $2.0M $1.8M $1.5M $1.0M $0.9M $0.8M $0.7M $0.4M $0.5M
Goodwill — — — — — — $0.0M $4.7M $4.7M $4.7M
Intangible assets — — — — — — $0.0M $69.2M $69.0M $6.4M
Total assets $84.9M $52.5M $26.7M $10.5M $11.2M $133M $115M $172M $178M $285M
Total liabilities $104M $110M $93.3M $85.0M $77.6M $5.8M $40.2M $110M $138M $130M
Preferred stock $0.0M $0.0M — — — $0.0M $0.0M — $0.0M $0.0M
Shareholders' equity −$18.7M −$57.5M −$66.6M −$74.5M −$66.4M $102M $75.1M $61.9M $39.7M $155M
Margins
Gross margin — — — 22.1% — 92.8% 97.8% 89.3% — —
Operating margin — — — −158.4% −42.2% 27.0% −418.9% −180.6% −368.5% −59.1%
EBITDA margin — — — −156.0% −40.2% 27.9% −409.6% −177.0% −341.4% −55.3%
Net margin — — — −191.0% −96.0% −29.9% −263.5% −167.7% −446.9% 78.2%
FCF margin — — — −185.1% −14.8% 36.1% −185.1% −123.2% −295.0% −2.3%
Returns
Return on capital — — — — — — — — −231.6% −236.3%
Return on capital employed −47.9% −81.5% −379.2% −400.7% −152.7% 6.0% −41.2% −50.3% −60.4% −25.6%
Return on equity — — — — — −48.5% −30.3% −67.2% −207.8% 85.7%
Return on assets −19.5% −63.2% −142.6% −131.7% −117.5% −11.9% −21.6% −32.0% −60.2% 36.0%
Return on tangible equity — — — — — −61.9% −35.6% — — 54.1%
Growth
Revenue growth — — — — 3.5% 115.6% −64.5% 170.3% −14.0% 350.9%
FCF growth — — — — — — −282.0% — — —
Share count change — 0.4% 22.4% −89.7% 114.8% 647.7% — — — 23.8%
Financial health
Debt / equity — — — — — — — 0.1x 1.5x 0.4x
Interest coverage −6.8x −5.8x −10.2x −4.2x −1.2x 34.2x −127.1x −33.0x −11.8x −7.9x
Current ratio 11.2x 4.0x 2.0x 1.3x 1.1x 27.2x 7.7x 1.2x 2.5x 5.7x
Quick ratio 11.2x 4.0x 2.0x 1.3x 1.1x 27.2x 7.7x 1.2x 2.5x 5.6x
Capital allocation
Capex / revenue — — — 0.2% 0.2% 0.4% 0.9% 1.1% 0.0% 0.8%
Stock comp / revenue — — — 34.3% 18.7% 8.5% 42.3% 21.7% 63.1% 11.9%
Payouts / FCF — — — — — 27.2% — — — —
Quality scores
Piotroski F-score — — 1.0 3.0 3.0 4.0 2.0 2.0 2.0 5.0
Altman Z'' −2.6 −10.8 −38.9 −89.2 −78.9 17.6 −5.9 −8.4 −10.3 −0.8
Accruals ratio 15.6% −15.0% −5.7% −4.2% −99.7% −26.4% −6.5% −8.7% −20.5% 36.7%

Source: SEC EDGAR XBRL filings (CIK 0001434647). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open